Venus Remedies to collaborate with TEVA

For a block buster Anti-Cancer Drug

Venus Remedies announced that the Company has entered into a collaborative agreement with TEVA for a block buster Anti-Cancer Drug. This high potential drug is under patent protection till 2016 and is widely used for treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer having a market of more than $4 billion and estimated to increase to $5.4 billion by 2020 in the regulated markets of United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Company is already in association with TEVA for two Cephalosporins product business from EU market.

Powered by Capital Market - Live News